<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779467</url>
  </required_header>
  <id_info>
    <org_study_id>IRB5917</org_study_id>
    <nct_id>NCT00779467</nct_id>
  </id_info>
  <brief_title>Epidural Neostigmine for Labor Pain</brief_title>
  <official_title>Epidural Neostigmine Dose Response for the Treatment of Labor Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see which dose of epidural neostigmine is the best additive
      to use with the numbing medication used in an epidural during labor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is examining the use of the non-narcotic medication, neostigmine, in combination
      with the local anesthetic bupivacaine when compared with the commonly used narcotic fentanyl
      in providing pain relief with the fewest side effects in labor analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Drug Consumed Per Hour in Each Group(Arm)</measure>
    <time_frame>until delivery</time_frame>
    <description>Median hourly total bupivacaine consumption. Drug amount consumed per hour of each group (arm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>until delivery</time_frame>
    <description>average maximum nausea score in each group--maternal nausea scored on a 0-no nausea at all up to maximum of 10-worst nausea imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>until delivery</time_frame>
    <description>average maternal sedation score measured on a 0-not sleepy at all up to a maximum of 10-extremely sleepy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shivering</measure>
    <time_frame>until delivery</time_frame>
    <description>maternal occurrence of shivering--Shivering scored on a 0-no shivering at all up to maximum of 10-shivering uncontrollably</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus</measure>
    <time_frame>until delivery</time_frame>
    <description>the occurrence of pruritis (itching) throughout the labor analgesia infusion--the presence of itching rated on a scale of 0-no itching at all up to a maximum of 10- severe itching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bromage Score</measure>
    <time_frame>until delivery</time_frame>
    <description>the incidence of decreased motor block (Bromage score) documented until delivery. Bromage is defined as 0-freely able to move extremities (no motor block) up to 3-unable to move legs or feet (complete motor block)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Scores</measure>
    <time_frame>within 24 hours post delivery</time_frame>
    <description>maternal reported satisfaction scores of labor analgesia on a scale of 1-5, with 1-not satisfied at all up to 5 -completely satisfied with labor analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cesarean Delivery</measure>
    <time_frame>occurence</time_frame>
    <description>percentage of subjects in each group requiring a ceserean delivery</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Labor Pain</condition>
  <arm_group>
    <arm_group_label>Bupivacaine with Neostimgine 8 mcg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine and Neostigmine 4 mcg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine with Neostigmine 2 mcg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BUPIVACAINE WITH FENTANYL 2 MCG/ML</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.</description>
    <arm_group_label>Bupivacaine with Neostimgine 8 mcg/ml</arm_group_label>
    <arm_group_label>Bupivacaine and Neostigmine 4 mcg/ml</arm_group_label>
    <arm_group_label>Bupivacaine with Neostigmine 2 mcg/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>Bupivacaine with Neostimgine 8 mcg/ml</arm_group_label>
    <arm_group_label>Bupivacaine and Neostigmine 4 mcg/ml</arm_group_label>
    <arm_group_label>Bupivacaine with Neostigmine 2 mcg/ml</arm_group_label>
    <arm_group_label>BUPIVACAINE WITH FENTANYL 2 MCG/ML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <description>fentanyl 2 mcg/ml</description>
    <arm_group_label>BUPIVACAINE WITH FENTANYL 2 MCG/ML</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy pregnancy

          -  Term pregnancy ( &gt; 37 weeks)

          -  Primiparous or multiparous

          -  Induction or spontaneous labor greater or = 18 years of age

          -  Cervical exam on entry &lt;/=5 cm

        Exclusion Criteria:

          -  Weight &gt; 115 kg

          -  Non-English speaking

          -  IV analgesics within 60 minutes prior to epidural being administered

          -  Allergy to local anesthetics or neostigmine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter H Pan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences OB Anesthesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <results_first_submitted>October 27, 2016</results_first_submitted>
  <results_first_submitted_qc>February 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non narcotic</keyword>
  <keyword>epidural</keyword>
  <keyword>labor pain</keyword>
  <keyword>Non narcotic treatment of labor pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
          <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
          <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
        </group>
        <group group_id="P3">
          <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
          <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
        </group>
        <group group_id="P4">
          <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
          <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>failed inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missing data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>technical issue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unavailable research staff</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
          <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
          <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
        </group>
        <group group_id="B3">
          <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
          <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
        </group>
        <group group_id="B4">
          <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
          <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="35"/>
            <count group_id="B5" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="5"/>
                    <measurement group_id="B2" value="27" spread="6"/>
                    <measurement group_id="B3" value="28" spread="6"/>
                    <measurement group_id="B4" value="27" spread="6"/>
                    <measurement group_id="B5" value="27.5" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amount of Drug Consumed Per Hour in Each Group(Arm)</title>
        <description>Median hourly total bupivacaine consumption. Drug amount consumed per hour of each group (arm)</description>
        <time_frame>until delivery</time_frame>
        <population>median hourly total bupivacaine consumption in each group, in ml/hr</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
            <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
            <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
            <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O4">
            <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
            <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Drug Consumed Per Hour in Each Group(Arm)</title>
          <description>Median hourly total bupivacaine consumption. Drug amount consumed per hour of each group (arm)</description>
          <population>median hourly total bupivacaine consumption in each group, in ml/hr</population>
          <units>milliliters per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="12" upper_limit="23"/>
                    <measurement group_id="O2" value="14.6" lower_limit="12" upper_limit="18"/>
                    <measurement group_id="O3" value="15.3" lower_limit="13" upper_limit="19"/>
                    <measurement group_id="O4" value="16" lower_limit="13" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea</title>
        <description>average maximum nausea score in each group--maternal nausea scored on a 0-no nausea at all up to maximum of 10-worst nausea imaginable</description>
        <time_frame>until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
            <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
            <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
            <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O4">
            <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
            <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea</title>
          <description>average maximum nausea score in each group--maternal nausea scored on a 0-no nausea at all up to maximum of 10-worst nausea imaginable</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.5"/>
                    <measurement group_id="O2" value="1.8" spread="3.0"/>
                    <measurement group_id="O3" value="1.8" spread="3.0"/>
                    <measurement group_id="O4" value="1.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedation</title>
        <description>average maternal sedation score measured on a 0-not sleepy at all up to a maximum of 10-extremely sleepy</description>
        <time_frame>until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
            <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
            <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
            <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O4">
            <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
            <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation</title>
          <description>average maternal sedation score measured on a 0-not sleepy at all up to a maximum of 10-extremely sleepy</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.0"/>
                    <measurement group_id="O2" value="3.4" spread="3.0"/>
                    <measurement group_id="O3" value="3.3" spread="2.9"/>
                    <measurement group_id="O4" value="4.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shivering</title>
        <description>maternal occurrence of shivering--Shivering scored on a 0-no shivering at all up to maximum of 10-shivering uncontrollably</description>
        <time_frame>until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
            <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
            <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
            <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O4">
            <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
            <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Shivering</title>
          <description>maternal occurrence of shivering--Shivering scored on a 0-no shivering at all up to maximum of 10-shivering uncontrollably</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.4"/>
                    <measurement group_id="O2" value="0.3" spread="0.4"/>
                    <measurement group_id="O3" value="0.3" spread="0.5"/>
                    <measurement group_id="O4" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pruritus</title>
        <description>the occurrence of pruritis (itching) throughout the labor analgesia infusion--the presence of itching rated on a scale of 0-no itching at all up to a maximum of 10- severe itching.</description>
        <time_frame>until delivery</time_frame>
        <population>the presence of itching rated on a scale of 0-no itching at all up to a maximum of 10- severe itching.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
            <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
            <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
            <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O4">
            <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
            <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Pruritus</title>
          <description>the occurrence of pruritis (itching) throughout the labor analgesia infusion--the presence of itching rated on a scale of 0-no itching at all up to a maximum of 10- severe itching.</description>
          <population>the presence of itching rated on a scale of 0-no itching at all up to a maximum of 10- severe itching.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.3"/>
                    <measurement group_id="O2" value="0.03" spread="0.2"/>
                    <measurement group_id="O3" value="0.03" spread="0.2"/>
                    <measurement group_id="O4" value="0.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bromage Score</title>
        <description>the incidence of decreased motor block (Bromage score) documented until delivery. Bromage is defined as 0-freely able to move extremities (no motor block) up to 3-unable to move legs or feet (complete motor block)</description>
        <time_frame>until delivery</time_frame>
        <population>Bromage is defined as 0-freely able to move extremities (no motor block) up to 3-unable to move legs or feet (complete motor block)</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
            <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
            <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
            <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O4">
            <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
            <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Bromage Score</title>
          <description>the incidence of decreased motor block (Bromage score) documented until delivery. Bromage is defined as 0-freely able to move extremities (no motor block) up to 3-unable to move legs or feet (complete motor block)</description>
          <population>Bromage is defined as 0-freely able to move extremities (no motor block) up to 3-unable to move legs or feet (complete motor block)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.7"/>
                    <measurement group_id="O2" value="1.1" spread="1.4"/>
                    <measurement group_id="O3" value="1.0" spread="0.9"/>
                    <measurement group_id="O4" value="0.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Scores</title>
        <description>maternal reported satisfaction scores of labor analgesia on a scale of 1-5, with 1-not satisfied at all up to 5 -completely satisfied with labor analgesia</description>
        <time_frame>within 24 hours post delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
            <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
            <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
            <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O4">
            <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
            <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction Scores</title>
          <description>maternal reported satisfaction scores of labor analgesia on a scale of 1-5, with 1-not satisfied at all up to 5 -completely satisfied with labor analgesia</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="4.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cesarean Delivery</title>
        <description>percentage of subjects in each group requiring a ceserean delivery</description>
        <time_frame>occurence</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
            <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
            <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
            <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
          </group>
          <group group_id="O4">
            <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
            <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Cesarean Delivery</title>
          <description>percentage of subjects in each group requiring a ceserean delivery</description>
          <units>percentage of subjects in each group</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine With Neostimgine 8 mcg/ml</title>
          <description>STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine and Neostigmine 4 mcg/ml</title>
          <description>STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
        </group>
        <group group_id="E3">
          <title>Bupivacaine With Neostigmine 2 mcg/ml</title>
          <description>STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
Neostigmine: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Bupivacaine</description>
        </group>
        <group group_id="E4">
          <title>BUPIVACAINE WITH FENTANYL 2 MCG/ML</title>
          <description>Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
Bupivacaine
fentanyl: fentanyl 2 mcg/ml</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter H. Pan, MD, MSEE</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-718-8278</phone>
      <email>ppan@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

